Ireland’s Mr IPO and his plans to make more companies public
Cathal Friel shows no sign of slowing down after a busy week which saw him sell his remaining stake in Hvivo
Cathal Friel shows no sign of slowing down after a busy week which saw him sell his remaining stake in Hvivo
Businessman oversaw the initial flotation in 2019 of clinical trials group that became Hvivo
New and existing institutional investors indicated demand for shares was in excess of those available
Pharmaceutical services company is testing drug for human rhinovirus in human challenge trial
Biopharmaceutical company hails work with CytoReason as ‘significant breakthrough’
Deal is Dublin-listed pharma company's first in the region in over 10 years
Company has been working with OneThree Biotech to us artificial intelligence to identify novel drug targets for RSV treatment
Leo Toole has stepped down from the board and CFO role to pursue other interests, company announced on Monday
Deal will see hVivo manufacture virus for use in human challenge studies
Company expects revenues from the contract to be recognised across 2022 and 2023
Cathal Friel to continue in executive chairman role under new management structure
Bavarian Nordic vaccine candidate used hVivo challenge trial to gather data
Executive chairman Cathal Friel said Hvivo expects to sign a number of similar contracts
Influenza could be a major global issue due to low immunity caused by reduced infection
Study is being carried out under asthma human challenge study model
Healthy volunteers are administered a pathogenic or virulent strain of virus
Challenge study is providing valuable insight into biology of the virus, firm says
Company will use money from listing to meet costs for flu drug trials, develop assets
Company says reduction of capital will allow it to return value to its shareholders
hVivo will develop a new SARS-CoV-2 challenge virus based on new emerging variants
Company says HVO-001 could be included as part of potential demerger
Contract with US biotechnology company concerns a respiratory syncytial virus
Irish clinical trials group will deliberately infect healthy young volunteers with virus
Prophylactic spray could be used against Covid-19
Dublin-listed pharmaceutical services company says new deal will run for another year
Vaccine could be one of the first to provide long-term immunity from Covid-19
Open Orphan subsidiary to manage Phase 2 clinical trial for European pharma company
Guidelines will cover manufacture of agents for use in controlled infection studies
‘All we have at this point is a very promising press release. But the signs are very promising’
Contract guarantees annual revenue for Dublin listed company
Contract with UK government could be worth up to £10m
Company led by Cathal Friel recorded revenues of £7.1m for its first half
Officials warn Covid infections across country ‘a week or two’ behind Dublin
Crosswords & puzzles to keep you challenged and entertained
Full general election coverage including analysis and results for all 43 constituencies
How does a post-Brexit world shape the identity and relationship of these islands
Weddings, Births, Deaths and other family notices